Essential role for B cells in transplantation tolerance

Current Opinion in Immunology

Volumn 23, Issue 5, 2011, Pages 685-691

  Redfield, Robert R ^a   Rodriguez, Eduardo ^a   Parsons, Ronald ^a   Vivek, Kumar ^a   Mustafa, Moiz M ^a   Noorchashm, Hooman ^a   Naji, Ali ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; B LYMPHOCYTE RECEPTOR; BORTEZOMIB; RAPAMYCIN; RITUXIMAB;

ALLOGRAFT; ANTIBODY TITER; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; REGULATORY B LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN PRESENTATION; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINEAGE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; ISOANTIBODIES; ISOANTIGENS; MICE; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 80053583779     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2011.07.011     Document Type: Review

References (49)

1. Colvin R.B., Hirohashi T., Farris A.B., Minnei F., Collins A.B., Smith R.N. Emerging role of B cells in chronic allograft dysfunction. Kidney Int Suppl 2010, S13-S17.
2. Terasaki P.I., Ozawa M., Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007, 7:408-415.
3. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005, 365:1570-1576.
4. Clatworthy M.R., Espeli M., Torpey N., Smith K.G. The generation and maintenance of serum alloantibody. Curr Opin Immunol 2010, 22:669-681.
5. Lund F.E., Randall T.D. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010, 10:236-247.
6. Sarwal M., Chua M.S., Kambham N., Hsieh S.C., Satterwhite T., Masek M., Salvatierra O. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003, 349:125-138.
7. Noorchashm H., Reed A.J., Rostami S.Y., Mozaffari R., Zekavat G., Koeberlein B., Caton A.J., Naji A. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 2006, 177:7715-7722.
8. Ng Y.L.Q., Marlowe A., Hoffman R., Chalasani G. Antigen presentation by B cells promotes heart allograft rejection and development of alloreactive memory T cells. Am J Transplant 2008, 8:269.
9. Liu C., Noorchashm H., Sutter J.A., Naji M., Prak E.L., Boyer J., Green T., Rickels M.R., Tomaszewski J.E., Koeberlein B., et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 2007, 13:1295-1298.
10. Kelishadi S.S., Azimzadeh A.M., Zhang T., Stoddard T., Welty E., Avon C., Higuchi M., Laaris A., Cheng X.F., McMahon C., et al. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. J Clin Invest 2010, 120:1275-1284.
11. Tyden G., Genberg H., Tollemar J., Ekberg H., Persson N.H., Tufveson G., Wadstrom J., Gabel M., Mjornstedt L. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009, 87:1325-1329.
12. Reichardt P., Dornbach B., Rong S., Beissert S., Gueler F., Loser K., Gunzer M. Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 2007, 110:1519-1529.
13. Chen X., Jensen P.E. Cutting edge: primary B lymphocytes preferentially expand allogeneic FoxP3+CD4 T cells. J Immunol 2007, 179:2046-2050.
14. Fuchs E.J., Matzinger P. B cells turn off virgin but not memory T cells. Science 1992, 258:1156-1159.
15. Deng S., Moore D.J., Huang X., Lian M.M., Mohiuddin M., Velededeoglu E., Lee MKt, Sonawane S., Kim J., Wang J., et al. Cutting edge: transplant tolerance induced by anti-CD45RB requires B lymphocytes. J Immunol 2007, 178:6028-6032.
16. Chen X., Jensen P.E. The role of B lymphocytes as antigen-presenting cells. Arch Immunol Ther Exp (Warsz) 2008, 56:77-83.
17. DiLillo D.J., Griffiths R., Seshan S.V., Magro C.M., Ruiz P., Coffman T.M., Tedder T.F. B lymphocytes differentially influence acute and chronic allograft rejection in mice. J Immunol 2011, 186:2643-2654.
18. Clatworthy M.R., Watson C.J., Plotnek G., Bardsley V., Chaudhry A.N., Bradley J.A., Smith K.G. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009, 360:2683-2685.
19. Thaunat O., Morelon E., Defrance T. Am'B'valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 2010, 116:515-521.
20. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361:2143-2152.
21. Kopchaliiska D., Zachary A.A., Montgomery R.A., Leffell M.S. Reconstitution of peripheral allospecific CD19+B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients. Transplantation 2009, 87:1394-1401.
22. Newell K.A., Asare A., Kirk A.D., Gisler T.D., Bourcier K., Suthanthiran M., Burlingham W.J., Marks W.H., Sanz I., Lechler R.I., et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010, 120:1836-1847.
23. Sagoo P., Perucha E., Sawitzki B., Tomiuk S., Stephens D.A., Miqueu P., Chapman S., Craciun L., Sergeant R., Brouard S., et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010, 120:1848-1861.
24. Chung J.B., Wells A.D., Adler S., Jacob A., Turka L.A., Monroe J.G. Incomplete activation of CD4 T cells by antigen-presenting transitional immature B cells: implications for peripheral B and T cell responsiveness. J Immunol 2003, 171:1758-1767.
25. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., Anderton S.M. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950.
26. Mauri C., Gray D., Mushtaq N., Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003, 197:489-501.
27. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002, 16:219-230.
28. Lenert P., Brummel R., Field E.H., Ashman R.F. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005, 25:29-40.
29. Blair P.A., Norena L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., Mauri C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32:129-140.
30. Carter N.A., Vasconcellos R., Rosser E.C., Tulone C., Munoz-Suano A., Kamanaka M., Ehrenstein M.R., Flavell R.A., Mauri C. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 2011, 186:5569-5579.
31. Shlomchik M.J. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008, 28:18-28.
32. Parsons R.F., Vivek K., Rostami S.Y., Zekavat G., Ziaie S.M., Luo Y., Koeberlein B., Redfield R.R., Cancro M.P., Naji A., et al. Acquisition of humoral transplantation tolerance upon de novo emergence of B lymphocytes. J Immunol 2010, 186:614-620.
33. Li Y., Ma L., Shen J., Chong A.S. Peripheral deletion of mature alloreactive B cells induced by costimulation blockade. Proc Natl Acad Sci U S A 2007, 104:12093-12098.
34. Fan X., Ang A., Pollock-Barziv S.M., Dipchand A.I., Ruiz P., Wilson G., Platt J.L., West L.J. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 2004, 10:1227-1233.
35. Urschel S., Campbell P.M., Meyer S.R., Larsen I.M., Nuebel J., Birnbaum J., Netz H., Tinckam K., Kauke T., Derkatz K., et al. Absence of donor-specific anti-HLA antibodies after ABO-incompatible heart transplantation in infancy: altered immunity or age?. Am J Transplant 2009, 10:149-156.
36. Parsons R.F., Vivek K., Redfield R.R., Migone T.S., Cancro M.P., Naji A., Noorchashm H. B-cell tolerance in transplantation: is repertoire remodeling the answer?. Expert Rev Clin Immunol 2009, 5:703.
37. Miller J.P., Stadanlick J.E., Cancro M.P. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol 2006, 176:6405-6410.
38. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., Frew E., Scott M.L. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293:2111-2114.
39. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
40. Parsons R.F., Vivek K., Redfield R.R., Migone T.S., Cancro M.P., Naji A., Noorchashm H. B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. Transplant Rev (Orlando) 2010, 24:207-221.
41. Zekavat G., Rostami S.Y., Badkerhanian A., Parsons R.F., Koeberlein B., Yu M., Ward C.D., Migone T.S., Yu L., Eisenbarth G.S., et al. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J Immunol 2008, 181:8133-8144.
42. Walters S., Webster K.E., Sutherland A., Gardam S., Groom J., Liuwantara D., Marino E., Thaxton J., Weinberg A., Mackay F., et al. Increased CD4+Foxp3+T cells in BAFF-transgenic mice suppress T cell effector responses. J Immunol 2009, 182:793-801.
43. Radbruch A., Muehlinghaus G., Luger E.O., Inamine A., Smith K.G., Dorner T., Hiepe F. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006, 6:741-750.
44. Fairfax K.A., Kallies A., Nutt S.L., Tarlinton D.M. Plasma cell development: from B-cell subsets to long-term survival niches. Semin Immunol 2008, 20:49-58.
45. Stegall M.D., Gloor J., Winters J.L., Moore S.B., Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006, 6:346-351.
46. Chu V.T., Frohlich A., Steinhauser G., Scheel T., Roch T., Fillatreau S., Lee J.J., Lohning M., Berek C. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 2011, 12:151-159.
47. Benson M.J., Dillon S.R., Castigli E., Geha R.S., Xu S., Lam K.P., Noelle R.J. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008, 180:3655-3659.
48. Neubert K., Meister S., Moser K., Weisel F., Maseda D., Amann K., Wiethe C., Winkler T.H., Kalden J.R., Manz R.A., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008, 14:748-755.
49. Diwan T.S., Raghavaiah S., Burns J.M., Kremers W.K., Gloor J.M., Stegall M.D. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation 2011, 91:536-541.